Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 2, 1998, Pages 700-706

  Mytilineou, Catherine ^a   Leonardi, Efthimia Kototos ^a   Radcliffe, Pheona ^a   Heinonen, Esa H ^a   Han, Shan Kuo ^a   Werner, Peter ^a   Cohen, Gerald ^a   Olanow, C Warren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BUTHIONINE SULFOXIMINE; DESMETHYLSELEGILINE; DRUG METABOLITE; GLUTATHIONE; LACTATE DEHYDROGENASE; MAZINDOL; PARGYLINE; SELEGILINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; FEMALE; MESENCEPHALON; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

AMPHETAMINES; ANIMALS; ASCORBIC ACID; BUTHIONINE SULFOXIMINE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; MAZINDOL; MESENCEPHALON; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARGYLINE; RATS; SELEGILINE; TYROSINE 3-MONOOXYGENASE;

EID: 0031886449     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Ahola T, Haapalinna A, Heinonen E, Suhonen J and Hervonen A (1993) 6-OHDA neurotoxicity is prevented by selegiline and its metabolites. Soc Neurosci Abstr 20:674.2.
2. Barrett JS, Szego P, Rohatagi S, Morales RJ, DeWitt KE, Rajewski G and Ireland J (1996) Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res 13:1535-1540.
3. Bergmeyer H-U, Bernt E and Hess B (1963) Lactic dehydrogenase, in Methods of Enzymatic Analysis (Bergmeyer H-U, ed) pp 736-741, Academic Press, New York.
4. Bhave SV, Johannessen JN, Lash LH, Wakade TD and Wakade AR (1996) Age-dependent sensitivity of cultured peripheral sympathetic neurons to 1-methyl-4-phenylpyridinium: role of glutathione. J Neurochem 67:557-565.
5. Borbe HO, Niebch G and Nickel B (1990) Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in rat. J Neural Transm 32(Suppl.):131-137.
6. Bronzetti E, Felici L, Ferrante F and Valsecchi B (1992) Effect of ethylcholine mustard aziridinium (AF64A) and of the monoamine oxidase-B-inhibitor L-deprenyl on the morphology of the rat hippocampus. Int J Tissue React XIV:175-182.
7. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K and Ivy GO (1994a) The effect of a long-term (6 months) treatment with (-)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem Pharmacol 47:1333-1338.
8. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K and Ivy GO (1994b) (-)Deprenyl increases activities of Superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci 54:975-981.
9. Carrillo MC, Ivy GO, Milgram NW, Head E, Wu P and Kitani K (1994c) (-)-Deprenyl increases activities of superoxide dismutase (SOD) in striatum of dog brain. Life Sci 54:1483-1489.
10. Chiueh CC, Huang S-J and Murphy DL (1994) Suppression of hydroxyl radical formation by MAO inhibitors: A novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J Neural Trans 41(Suppl.) :189-196.
11. Cohen G (1983) The pathobiology of Parkinson's disease: Biochemical aspects of dopamine neuron senescence. J Neural Transm 19(Suppl.):89-103.
12. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel SE, Lees AJ, Schapira MD, Jenner P and Marsden CD (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 35:38-44.
13. Fang J and Yu PH (1994) Effect of L-deprenyl, its structural analogs and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacol 33:763-768.
14. Finnegan KT, Skratt JJ, Irwin I, DeLanney LE and Langston JW (1990) Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 184:119-126.
15. Gramsbergen JBP, Sebens JB and Korf J (1986) In vivo labeling and axonal transport of monoamine oxidase in the rat basal ganglia using radioactive pargyline. J Neural Transm 66:21-36.
16. Griffith OW and Meister A (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254:7558-7560.
17. Haapalinna A, MacDonald E, Nyman L and Heinonen E (1997) The neuroprotective effect of selegiline and its metabolites against DSP-4 is caused without connection to MAO-B inhibition. Mou Disord 12(Suppl. 1):P136.
18. Heinonen EH, Antilla MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykkö KA and Lammintausta RAS (1997) Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase B in humans. J Clin Pharmacol 37:602-609.
19. Heinonen EH, Antilla MI and Lammintausta RA (1994) Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 56:742-749.
20. Jain A, Mårtensson J, Stole E, Auld PAM and Meister A (1991) Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 88:1913-1917.
21. Jenner P and Olanow CW (1996) Oxidative stress in the pathogenesis of Parkinson's disease. Neurology 47:161-170.
22. Knoll J (1978) The possible mechanism of action of (-)-deprenyl in Parkinson's disease. J Neural Transm 43:177-198.
23. Knoll J and Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393-408.
24. Knollema S, Aukema W, Hom H, Korf J and Ter Horst JG (1995) L-Deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 26:1883-1887.
25. Koutsilieri E, Chen T-S, Rausch W-D and Riederer P (1996) Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium. Eur J Pharmacol 306:181-186.
26. Kushleika J, Checkoway H, Woods JS, Moon J-D, Smith-Weller T, Franklin GM and Swanson PD (1996) Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Ann Neurol 39:378-381.
27. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
28. Mårtensson J, Jain A, Stole E, Frayer W, Auld PA and Meister A (1991) Inhibition of glutathione synthesis in the newborn rat: A model of endogenously produced oxidative stress. Proc Natl Acad Sci USA 88:9360-9364.
29. Mårtensson J and Meister A (1991) Glutathione deficiency decreases tissue ascorbate levels in newborn rats: Ascorbate spares glutathione and protects. Proc Natl Acad Sci USA 88:4656-4660.
30. Meister A (1991) Glutathione deficiency produce by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 51:155-194.
31. Myllylä VV, Sotaniemi KA, Vuorinen JA and Heinonen EE (1992) Selegiline as initial treatment in de novo parkinsonian patients. Neurology 42:339-343.
32. Mytilineou C and Cohen G (1985) Deprenyl protects dopaminergic neurons from the neurotoxic effects of 1-methyl-4-phenylpyridinium ion. J Neurochem 45:1951-1953.
33. Mytilineou C, Han SK and Cohen G (1993) Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 61:1470-1478.
34. Mytilineou C, Radcliffe P, Leonardi Kokotos E, Werner P and Olanow WC (1997a) L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem 68:33-39.
35. Mytilineou C, Radcliffe PM and Olanow CW (1997b) L-(-)-Desmethylselegiline, a metabolite of selegiline, protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 68:434-436.
36. Neff NH and Goridis C (1972) Neuronal monoamine oxidase: Specific enzyme types and their rates of formation, in Monoamine Oxidases: New Vistas (Costa E and Sandler M, eds) pp 307-323, Raven Press, New York.
37. Olanow CW and Calne D (1992) Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 42:13-26.
38. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W and Hubble J (1995) The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38:771-777.
39. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321:1364-1371.
40. Parkinson Study Group (1993) Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328:176-183.
41. Pileblad E, Magnusson T and Fornstedt B (1989) Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depletion action of 6-hydroxydopamine in rat striatum. J Neurochem 52:978-980.
42. Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K and Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-520.
43. Roy E and Bedard PJ (1993) L-Deprenyl increases survival of rat foetal nigral neurones in culture. NeuroReport 4:1183-1186.
44. Salo PT and Tatton WG (1992) L-Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31:394-400.
45. Salonen T, Haapalinna A, Heinonen E, Suhonen J and Hervonen A (1996) Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol 91:466-474.
46. Schulzer M, Mak E and Calne DB (1992) The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 32:795-798.
47. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P and Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355.
48. Sivenius J, Kuhmonen J, Miettinen R, Haapalinna A and Riekkinen P Jr (1994) Effect of selegiline on the hippocampal CA1 layer following transient ischemia in gerbil. Soc Neurosci Abstr 20:83.5.
49. Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D and Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology 86:432-437.
50. Sziráki I, Kardos V, Patthy M, Pátfalusi M, Gaál J, Solti M, Kollár E and Singer J (1994) Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2′-methyl-MPTP. J Neural Transm 47(Suppl.): 207-219.
51. Tatton WG and Chalmers-Redman RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration. Neurology 47(Suppl. 3):171-183.
52. Tatton WG and Greenwood CE (1991) Rescue of dying neurons: A new action for L-deprenyl in MPTP parkinsonism. J Neurosci Res 30:666-672.
53. Tatton WG, Ju WYL, Holland DP, Tai C and Kwan M (1994) (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572-1575.
54. Tetrud JW and Langsten JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245:519-522.
55. Thiffault C, Aumont N, Quirion R and Poirier J (1995) Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem 65:2725-2733.
56. Thomas CE, Huber EW and Ohlweiler DF (1997) Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: Implications for protection of biological amines. Free Rad Biol Med 22:733-737.
57. Tietze F (1969) Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal Biochem 27:502-522.
58. + in vivo. Eur J Pharmacol 243:241-247.
59. + toxicity in nigral dopaminergic neurons. NeuroReport 7:921-923.
60. Yoshida T, Yamada Y, Yamamoto T and Kuroiwa Y (1986) Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to MAO-B inhibitory activity. Xenobiotica 16:129-136.
61. Zeevalk GD, Bernard LP, Albers DS, Mirochnitchenko O, Nicklas WJ and Sonsalla PK (1997) Energy stress-induced dopamine loss in glutathione peroxidase-overexpressing transgenic mice and in glutathione-depleted mesencephalic cultures. J Neurochem 68:426-429.
62. Zhong L-T, Sarafinn T, Kane DJ, Charles AC, Mah SP, Edwards RH and Bredesen DE (1993) Bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Nat Acad Sci USA 90:4533-4537.
63. Zsilla G, Földi P, Held G, Székely AM and Knoll J (1986) The effect of repeated doses of (-)-deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol J Pharmacol Pharm 38:57-67.